Zuclopenthixol Short-acting Intramuscular Injection bulk supplier for pharma manufacturers

Zuclopenthixol Short-Acting Intramuscular Injection 50 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Short-acting Intramuscular Injection

Available Strengths: 50 mg/mL

Reference Brands: Clopixol-Acuphase®

Zuclopenthixol short-acting IM injection is a typical antipsychotic that works by blocking dopamine D2 receptors, helping to rapidly reduce symptoms of acute psychosis and agitation. It is primarily used in emergency settings to calm aggressive or severely disturbed patients with schizophrenia or related psychotic disorders, offering quick symptom control

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Zuclopenthixol Short-Acting Intramuscular Injection? List it or send an offer →

Product Description: Zuclopenthixol short-acting intramuscular injection, commonly used in acute psychosis and agitation, is not currently approved by the FDA in the United States but is available in several EU markets under Clopixol-Acuphase. In the EU, it follows EMA regulatory standards for parenteral antipsychotics, requiring GMP compliance, stability data, and clinical justification for emergency psychiatric use. U.S. registration would require a detailed regulatory strategy, including an IND or 505(b)(2) approach. To explore other dosage forms, strengths, and dossier-ready Zuclopenthixol IM injection products, visit Pharmatradz.com — your trusted global B2B platform for API and finished formulations.

Zuclopenthixol Short-Acting Intramuscular Injection — third party manufacturing & bulk supply

Zuclopenthixol Short-Acting Intramuscular Injection 50 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Zuclopenthixol Short-Acting Intramuscular Injection is supplied as Short-acting Intramuscular Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Zuclopenthixol Short-Acting Intramuscular Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Zuclopenthixol Short-Acting Intramuscula... →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Zuclopenthixol Short-acting Intramuscular Injection is listed as Short-acting Intramuscular Injection in 50 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Zuclopenthixol Short-acting Intramuscular Injection is referenced against Clopixol-Acuphase®. Reference brands are shown for identification only and remain the property of their respective trademark owners.